A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy

A PHASE 1B MULTICENTER, OPEN-LABEL, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF-06939926 IN AMBULATORY AND NON-AMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY

This is a first-in-human/first-in-patient, multi-center, open-label, non-randomized, ascending dose, safety and tolerability study of a single intravenous infusion of PF-06939926 in ambulatory and non-ambulatory subjects with Duchenne muscular dystrophy (DMD). Other objectives include measurement of dystrophin expression and distribution, and assessments of muscle strength, quality, and function.

A total of approximately 22 subjects will receive PF-06939926, and these will include both ambulatory and non-ambulatory subjects. Up to 13 subjects may be included in a cohort that includes the concomitant medication, sirolimus. In order to mitigate unanticipated risks to subject safety, enrollment will be staggered within and between two planned dose-levels and will include a formal review by an external data monitoring committee (E-DMC) prior to dose progression.

Inclusion Criteria:

• Age as follows, based on ambulatory status:

  • FOR AMBULATORY PARTICIPANTS, defined as the ability to walk at least 10 meters unassisted: Between 4 and 12 years, inclusive,
  • FOR NON-AMBULATORY PARTICIPANTS, defined as the inability to walk at least 10 meters unassisted: No age restrictions so long as loss of ambulation occurs prior to the subject's 17th birthday;

• Diagnosis of Duchenne muscular dystrophy confirmed by medical history and genetic testing;

• Receipt of glucocorticoids for 6 months and a stable daily dose for at least 3 months prior to study entry;

• Ability to tolerate magnetic resonance imaging (MRI) without sedation and with no contraindications to these procedures;

• Ability to tolerate muscle biopsies under anesthesia with no contraindications to these procedures;

• Body weights as follows, based on ambulatory status:

  • FOR AMBULATORY PARTICIPANTS: Between 15 kg and 50 kg,
  • FOR NON-AMBULATORY PARTICIPANTS: Less than 75 kg, but which may be managed or adjusted to a lower limit, especially to ensure participant safety;

• Functional performance as follows, based on ambulatory status:

  • FOR AMBULATORY PARTICIPANTS: Ability to rise from floor within seven (7) seconds,
  • FOR NON-AMBULATORY PARTICIPANTS: Percent predicted forced vital capacity greater than 40% as part of pulmonary function tests, as well as adequate upper limb function.

Exclusion Criteria:

• Receipt of live attenuated vaccination within 3 months prior to receiving PF-06939926 or exposure to an influenza (or other inactivated) vaccination or systemic antiviral and/or interferon therapy within 30 days prior to receipt of PF-06939926;

• Prior exposure to any gene therapy agent, including exon-skipping agents;

• Exposure to other investigational drugs within 30 days or 5 half-lives, whichever is longer;

• Neutralizing antibodies (NAb) against adeno-associated virus, serotype 9 (AAV9);

• Compromised cardiac function as indicated by left ventricular ejection fraction on cardiac MRI, as follows, based on ambulatory status:

  • FOR AMBULATORY PARTICIPANTS: Less than 55%,
  • FOR NON-AMBULATORY PARTICIPANTS: Less than 35%;

• Inadequate hepatic or renal function or risk factors for autoimmune disease on screening laboratory assessments.

• The following genetic abnormalities in the dystrophin gene as confirmed by the investigator based on the review of the DMD genetic testing:

  1. Any mutation (exon deletion, exon duplication, insertion, or point mutation) affecting any exon between exon 9 and exon 13, inclusive; OR
  2. A deletion that affects both exon 29 and exon 30.

Sirolimus Cohort

Inclusion Criteria

• > 8 years of age Exclusion Criteria
• Hypersensitivity to sirolimus or intolerance to soy, including a history of angioedema
• Concomitant use with strong CYP3A4/P-gp inducers or inhibitors